Physician profile
David M Pope
NPI 1467554451
$2,490.51
in general payments reported to CMS, 2019-2025
32 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $574 · 2021: $530 · 2022: $469 · 2023: $350 · 2024: $196 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $398.11 | 2020-2023 | Jardiance, Mounjaro, Emgality |
| Astrazeneca Pharmaceuticals LP | $316.78 | 2020-2025 | Farxiga, Breztri |
| Abbvie INC. | $276.12 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.74 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $155.79 | 2020-2025 | Enflonsia, Capvaxive |
| Pfizer INC. | $139.03 | 2019-2024 | |
| Novo Nordisk INC | $120.94 | 2019-2025 | Rybelsus, Ozempic |
| Eisai INC. | $104.99 | 2020-2021 | |
| Glaxosmithkline, LLC. | $75.11 | 2019-2022 | |
| Allergan, INC. | $73.29 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $71.56 | 2020-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $67.93 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $50.81 | 2021 | |
| Amarin Pharma, INC. | $47.90 | 2020 | |
| Idorsia Pharmaceuticals US INC | $40.88 | 2023 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $38.41 | 2021 | |
| Corcept Therapeutics | $36.68 | 2024-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.90 | 2025 | Caplyta |
| Horizon Therapeutics Plc | $31.25 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.01 | 2022 | |
| Baxter Healthcare | $23.15 | 2023 | Hillrom - Life 2000 Ventilation System |
| Organogenesis INC. | $22.55 | 2022 | |
| Sunovion Pharmaceuticals INC. | $21.85 | 2019 | |
| Sanofi Pasteur INC. | $21.40 | 2025 | |
| Indivior INC. | $19.21 | 2025 | Sublocade |
| Actelion Pharmaceuticals US, INC. | $19.06 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.38 | 2023 | Qelbree |
| Medtronic, INC. | $15.20 | 2023 | Minimed 770g |
| Organon LLC | $13.87 | 2025 | Nexplanon |
| Tactile Systems Technology INC | $13.08 | 2020 | |
| Orthofix Medical, INC. | $12.63 | 2025 | Physio-Stim |
| Alkermes, INC. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.